MYCO-005

Last updated
MYCO-005
Clinical data
Other namesMYCO005
Drug class Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen [1] [2] [3]

MYCO-005 is a serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of depressive disorders and anxiety disorders. [1] [2] [4] [3] [5]

It is an aza-indole analogue of psilocin and hence a tryptamine relative. [1] [3] [6] However, whereas psilocin and other tryptamines show high affinity for and potent activation of not only the serotonin 5-HT2A receptor but also the serotonin 5-HT2B receptor, MYCO-005 does not bind to this receptor. [1] [3] Activation of the serotonin 5-HT2B receptor is known to induce the development of cardiac valvulopathy and has been a concern with regard to chronic microdosing of psychedelics. [7] [8] Since MYCO-005 does not activate the serotonin 5-HT2B receptor, it is anticipated to be heart-safe and to be safer for use in the contexts of both macro- and microdosing than other psychedelics. [1] [3] [5]

As of February 2024, MYCO-005 is in the research stage of development for depressive disorders and anxiety disorders. [1] It is being developed by Mydecine. [1] [2] The exact chemical structure of MYCO-005 does not yet seem to have been disclosed. [1] However, the compound was patented in 2023 and the specified patent specifically describes aza-substituted psilocin analogues. [5] [9]

See also

References

  1. 1 2 3 4 5 6 7 8 "Research programme: second generation psilocin analogs". AdisInsight. 13 February 2024. Retrieved 1 November 2024. A family of psilocin analogs (MYCO 005) with heart-safe microdose enabling properties is being developed by Mydecine Innovations Group for the treatment of [...]
  2. 1 2 3 "Delving into the Latest Updates on MYCO-005 with Synapse". Synapse. 1 November 2024. Retrieved 1 November 2024.
  3. 1 2 3 4 5 "Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules". BioSpace. 16 February 2022. Retrieved 1 November 2024.
  4. ↑ "MYCO-005 Drug Profile". Ozmosi. 26 October 2023. Retrieved 1 November 2024.
  5. 1 2 3 Mydecine Innovations Group (18 December 2023). "Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound". Yahoo Finance. Retrieved 1 November 2024.
  6. ↑ "Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds". BioSpace. 7 February 2024. Retrieved 27 March 2025.
  7. ↑ Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R (September 2023). "The risk of chronic psychedelic and MDMA microdosing for valvular heart disease". J Psychopharmacol. 37 (9): 876–890. doi:10.1177/02698811231190865. PMID   37572027.
  8. ↑ Rouaud A, Calder AE, Hasler G (March 2024). "Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins". J Psychopharmacol. 38 (3): 217–224. doi:10.1177/02698811231225609. PMC   10944580 . PMID   38214279.
  9. ↑ "Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same". Google Patents. 1 May 2023. Retrieved 1 November 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.